PDCD1 and melanoma: Efficacy results (PFS, OS, and ORR) were similar to the data obtained in trials with PD-1 ICI in the advanced melanoma setting, even taking into account the different response evaluation criteria (Response Evaluation Criteria in Solid Tumors (RECIST) versus immune-related response criteria) [1,2,3].